Alnylam Pharmaceuticals (NASDAQ:ALNY) Director Paul Schimmel sold 15,000 shares of Alnylam Pharmaceuticals stock on the open market in a transaction dated Friday, December 20th. The shares were sold at an average price of $65.00, for a total transaction of $975,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 0.38% during mid-day trading on Tuesday, hitting $65.48. The stock had a trading volume of 26,973 shares. Alnylam Pharmaceuticals has a 52 week low of $17.31 and a 52 week high of $67.97. The stock has a 50-day moving average of $58.42 and a 200-day moving average of $51.5. The company’s market cap is $4.153 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 46.4% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.38 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ALNY shares. Analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $82.00 in a research note to investors on Monday, November 11th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Friday, November 8th. They now have a $53.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Wednesday, October 9th. They now have a $60.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $62.25.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.